Annual EBITDA:
-$143.10M-$31.34M(-28.04%)Summary
- As of today, TNGX annual EBITDA is -$143.10 million, with the most recent change of -$31.34 million (-28.04%) on December 31, 2024.
- During the last 3 years, TNGX annual EBITDA has fallen by -$85.80 million (-149.76%).
- TNGX annual EBITDA is now -177.95% below its all-time high of -$51.48 million, reached on December 31, 2020.
Performance
TNGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$40.34M+$1.57M(+3.74%)Summary
- As of today, TNGX quarterly EBITDA is -$40.34 million, with the most recent change of +$1.57 million (+3.74%) on June 30, 2025.
- Over the past year, TNGX quarterly EBITDA has dropped by -$11.42 million (-39.50%).
- TNGX quarterly EBITDA is now -8068300.00% below its all-time high of -$500.00, reached on June 30, 2020.
Performance
TNGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$154.80M-$11.42M(-7.97%)Summary
- As of today, TNGX TTM EBITDA is -$154.80 million, with the most recent change of -$11.42 million (-7.97%) on June 30, 2025.
- Over the past year, TNGX TTM EBITDA has dropped by -$24.84 million (-19.11%).
- TNGX TTM EBITDA is now -30959100.00% below its all-time high of -$500.00, reached on June 30, 2020.
Performance
TNGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TNGX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -28.0% | -39.5% | -19.1% |
| 3Y3 Years | -149.8% | -64.5% | -72.0% |
| 5Y5 Years | -177.9% | -10000.0% | -482.9% |
TNGX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -149.8% | at low | -85.6% | +3.7% | -55.8% | at low |
| 5Y | 5-Year | -177.9% | at low | -885.4% | +3.7% | -482.9% | at low |
| All-Time | All-Time | -177.9% | at low | >-9999.0% | +3.7% | >-9999.0% | at low |
TNGX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$40.34M(+3.7%) | -$154.80M(-8.0%) |
| Mar 2025 | - | -$41.91M(-4.0%) | -$143.37M(-0.2%) |
| Dec 2024 | -$143.10M(-28.0%) | -$40.29M(-24.9%) | -$143.10M(-4.3%) |
| Sep 2024 | - | -$32.26M(-11.5%) | -$137.20M(-5.6%) |
| Jun 2024 | - | -$28.92M(+30.5%) | -$129.96M(-5.8%) |
| Mar 2024 | - | -$41.63M(-21.0%) | -$122.78M(-11.6%) |
| Dec 2023 | -$111.76M(-2.1%) | -$34.40M(-37.5%) | -$109.98M(-5.0%) |
| Sep 2023 | - | -$25.01M(-15.1%) | -$104.69M(+3.4%) |
| Jun 2023 | - | -$21.74M(+24.6%) | -$108.39M(+2.5%) |
| Mar 2023 | - | -$28.83M(+1.0%) | -$111.16M(-3.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$109.46M(-91.1%) | -$29.11M(-1.4%) | -$107.04M(-7.8%) |
| Sep 2022 | - | -$28.70M(-17.1%) | -$99.33M(-10.4%) |
| Jun 2022 | - | -$24.52M(+0.8%) | -$90.00M(-29.4%) |
| Mar 2022 | - | -$24.71M(-15.4%) | -$69.58M(-23.1%) |
| Dec 2021 | -$57.29M(-11.3%) | -$21.41M(-10.5%) | -$56.51M(-29.6%) |
| Sep 2021 | - | -$19.37M(-373.1%) | -$43.61M(+14.1%) |
| Jun 2021 | - | -$4.09M(+64.8%) | -$50.80M(-8.8%) |
| Mar 2021 | - | -$11.63M(-36.7%) | -$46.70M(-33.2%) |
| Dec 2020 | -$51.48M | -$8.51M(+68.0%) | -$35.07M(-32.0%) |
| Sep 2020 | - | -$26.56M(>-9900.0%) | -$26.56M(>-9900.0%) |
| Jun 2020 | - | -$500.00 | -$500.00 |
FAQ
- What is Tango Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Tango Therapeutics, Inc.?
- What is Tango Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Tango Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Tango Therapeutics, Inc.?
- What is Tango Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Tango Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Tango Therapeutics, Inc.?
- What is Tango Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Tango Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of TNGX is -$143.10M
What is the all-time high annual EBITDA for Tango Therapeutics, Inc.?
Tango Therapeutics, Inc. all-time high annual EBITDA is -$51.48M
What is Tango Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, TNGX annual EBITDA has changed by -$31.34M (-28.04%)
What is Tango Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of TNGX is -$40.34M
What is the all-time high quarterly EBITDA for Tango Therapeutics, Inc.?
Tango Therapeutics, Inc. all-time high quarterly EBITDA is -$500.00
What is Tango Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, TNGX quarterly EBITDA has changed by -$11.42M (-39.50%)
What is Tango Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of TNGX is -$154.80M
What is the all-time high TTM EBITDA for Tango Therapeutics, Inc.?
Tango Therapeutics, Inc. all-time high TTM EBITDA is -$500.00
What is Tango Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, TNGX TTM EBITDA has changed by -$24.84M (-19.11%)